http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2421221-C1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_40564a13f6a73b84e2b8e8c9e15d1e44
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
filingDate 2010-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2011-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0c4bf6687afe3a7a33db8e489e04928
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1eab5ab97a894f806cc1ed21cee07c6e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1686b450221e23cb11cd4a794a975fea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b148b709139d3d1aa866f2ee023b7ae
publicationDate 2011-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2421221-C1
titleOfInvention Method of treating critical ischemia of lower extremities of various geneses
abstract FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to surgery, and concerns treating the patients with critical ischemia of lower extremities of various geneses. That is ensured by a complex background therapy of lower extremities involving intravenous drop introduction of SEROTONIN ADIPINATE 10 mg/day for 10 days with Mexicor added. For the first five days, Mexicor is administered once a day intra-arterially through a femoral catheter on an affected side in a daily dose 800 mg at rate 200 mg/hour. For the following five days, the intravenous drop introduction of Mexicor is performed by the schedule: at 6 o'clock - 200 mg; at 1400 - 300 mg; at 2200 - 300 mg dissolved in physiologic saline 100 ml at introduction rate 200-300 mg/hour. ^ EFFECT: method provides effective treatment and reduced number of failures in the form of amputation of the extremity due to improvement of microcirculation and elimination of reperfusion disorders in ischemic tissues. ^ 2 ex, 4 dwg
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2548739-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2673481-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2553429-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2491054-C1
priorityDate 2010-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4740
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419549034
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451639188
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5280427
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10964
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9913
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5202
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419492675
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419555446
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5234
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419486168
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407866699
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451961600
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4510
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6438834
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID27644
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419591862
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID452198223
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID76072982
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID196
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419474234
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448670727

Total number of triples: 42.